NCT00604786View on ClinicalTrials.gov

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Allergic Rhinitis
Interventions
DRUG

omalizumab

Dosing is based on IgE level and weight given every 2 or 4 weeks

DRUG

placebo

Dosing is based on IgE level and weight given every 2 or 4 weeks

Trial Locations (1)

21224

Johns Hopkins Asthma and Allergy Center, Baltimore

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Johns Hopkins University

OTHER

NCT00604786 - The Effect of Omalizumab on Responses to Cat Allergen Challenge | Biotech Hunter | Biotech Hunter